FDFT1: Cholesterol Target in Liver Cancer Unlocked by absin

I. Background: Unmet needs & new directions in HCC therapy

Liver cancer is the third leading cause of cancer-related death worldwide; hepatocellular carcinoma (HCC) accounts for ~90 %. Despite molecularly targeted agents, median overall survival for unresectable HCC remains <2 years. Dysregulated cholesterol metabolism is an established driver of hepatocarcinogenesis, yet statins display variable efficacy and dose-limiting toxicities. Identifying druggable nodes in the cholesterol-biosynthetic pathway is therefore urgently needed.

Farnesyl-diphosphate farnesyl-transferase 1 (FDFT1) catalyzes the first committed step of cholesterol synthesis. Its oncogenic role in HCC has remained unexplored. The present study systematically interrogated FDFT1 as a therapeutic target and delineated the underlying molecular circuitry.

II. Experimental design: a stepwise dissection of FDFT1-driven HCC progression

1. Target prioritization

Integration of TCGA, ICGC and GEO datasets nominated 23 cholesterol-biosynthetic genes. Differential-expression and univariate Cox analyses identified FDFT1 as the highest-ranking candidate that is consistently up-regulated in HCC and associated with poor prognosis.

2. Functional validation

CCK-8, colony formation, EdU, Transwell and wound-healing assays plus orthotopic-xenograft, tail-vein metastasis and DEN/CCl₄-induced HCC models were used to test both loss- and gain-of-function phenotypes.

• FDFT1 silencing: suppressed proliferation, migration, invasion and metastasis; reduced tumor burden; improved liver function.
• FDFT1 over-expression: accelerated tumor growth and metastasis.

3. Mechanistic elucidation

RNA-seq, Co-IP, ChIP–qPCR and rescue assays mapped the axis: FDFT1↓ → cholesterol & bile acids↓ → HNF4A transcriptional activity↑ → HNF4A occupies ALDOB promoter → ALDOB transcription↑ → ALDOB binds AKT1 and blocks its phosphorylation → HCC progression restrained.

4. Therapeutic exploration

Combination of FDFT1 knock-down with the AKT inhibitor capivasertib (AZD5363) was evaluated in vitro and in vivo to assess translational potential.

III. Key findings: four breakthroughs illuminating new HCC therapeutics

1. FDFT1 is an independent prognostic biomarker for poor HCC outcome

Multi-cohort analyses (TCGA, ICGC, n=90 IHC cohort) revealed FDFT1 up-regulation positively correlates with tumor size, distant metastasis and BCLC stage. High FDFT1 expression predicts shorter OS (P<0.0001) and higher metastatic risk (P=0.024) (Fig. 1).

2. FDFT1 reprograms cholesterol & bile-acid metabolism to fuel HCC

FDFT1 silencing decreased intracellular cholesterol and bile-acid pools, relieving their suppression on HNF4A. Exogenous cholesterol or chenodeoxycholic acid (CDCA) restored AKT phosphorylation and rescued the proliferative defect (Fig. 6).

3. HNF4A–ALDOB–AKT1 axis is the core signaling conduit

First demonstration that ALDOB acts as a metabolic checkpoint bridging cholesterol biosynthesis and PI3K/AKT signaling. ALDOB physically interacts with AKT1 to block its activating phosphorylation (Figs. 4E, 5G).

4. FDFT1 targeting synergizes with AKT inhibition

FDFT1 knock-down sensitized HCC cells to capivasertib. Combination therapy produced superior tumor growth inhibition versus single agents in both subcutaneous and orthotopic models (Fig. 7).

IV. Powered by absin: reliable tools for decisive experiments

Kit highlights:

• High specificity: Protein A/G Plus Agarose minimizes non-specific binding;
• Streamlined workflow: complete reagent set shortens hands-on time;
• Reproducible data: low background ensures confident detection of transient interactions.

V. Conclusions & outlook: from bench to bedside

This study establishes FDFT1 as a druggable metabolic vulnerability in HCC and uncovers the HNF4A–ALDOB–AKT1 axis as a previously unrecognized signaling bridge linking cholesterol biosynthesis to oncogenic PI3K/AKT signaling. FDFT1-targeted therapy, especially in combination with AKT inhibitors, offers a promising precision-oncology strategy that may overcome the limitations of conventional statins.

absin remains committed to supplying researchers with premium tools—from IP kits to antibodies and detection reagents—empowering breakthroughs in tumor metabolism, signaling and targeted therapy. We will continue to optimize product performance and accelerate translational innovation for the benefit of patients worldwide.

Cat. #	Product	Size
abs955	Immunoprecipitation (IP/CoIP) kit	50T
abs9649	Protein A/G Magnetic IP/Co-IP Kit	10T/50T
abs50034	ChIP Kit	22T
abs50074	DNA Pull Down Kit(Animal)	6T
abs50072	RNA Pull Down Kit	6T

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc. worldwide@absin.cn

Follow us on Facebook: Absin Bio